Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $45.0 million.

  • Zevra Therapeutics' Non-Current Assets fell 5114.38% to $45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.6 million, marking a year-over-year decrease of 579.76%. This contributed to the annual value of $13.4 million for FY2024, which is 2293.58% up from last year.
  • Per Zevra Therapeutics' latest filing, its Non-Current Assets stood at $45.0 million for Q3 2025, which was down 5114.38% from $29.9 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Non-Current Assets peaked at $92.1 million during Q3 2024, and registered a low of $2.0 million during Q3 2023.
  • For the 5-year period, Zevra Therapeutics' Non-Current Assets averaged around $27.4 million, with its median value being $17.9 million (2021).
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 9432.15% in 2023, then skyrocketed by 457795.84% in 2024.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Non-Current Assets stood at $17.9 million in 2021, then rose by 25.84% to $22.5 million in 2022, then crashed by 51.57% to $10.9 million in 2023, then rose by 22.94% to $13.4 million in 2024, then soared by 235.83% to $45.0 million in 2025.
  • Its last three reported values are $45.0 million in Q3 2025, $29.9 million for Q2 2025, and $12.3 million during Q1 2025.